Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Humankind Investments LLC

Humankind Investments LLC grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,879 shares of the medical equipment provider’s stock after acquiring an additional 196 shares during the period. Humankind Investments LLC’s holdings in Zimmer Biomet were worth $472,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. OLD Point Trust & Financial Services N A acquired a new position in Zimmer Biomet in the fourth quarter worth about $26,000. Naples Money Management LLC acquired a new position in Zimmer Biomet in the fourth quarter valued at approximately $35,000. Activest Wealth Management boosted its stake in Zimmer Biomet by 410.4% in the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 275 shares during the period. Blue Trust Inc. boosted its stake in Zimmer Biomet by 48.4% in the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock valued at $52,000 after acquiring an additional 153 shares during the period. Finally, Quent Capital LLC boosted its stake in Zimmer Biomet by 21.6% in the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock valued at $63,000 after acquiring an additional 92 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Shares of NYSE ZBH traded down $0.03 during trading on Friday, hitting $113.34. The company had a trading volume of 1,070,254 shares, compared to its average volume of 1,207,880. The company has a market cap of $23.32 billion, a P/E ratio of 24.53, a PEG ratio of 2.04 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $147.50. The business’s 50-day moving average is $120.60 and its 200 day moving average is $122.06. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The company had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the prior year, the company earned $1.89 earnings per share. The firm’s revenue was up 3.2% on a year-over-year basis. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend is Wednesday, June 26th. Zimmer Biomet’s payout ratio is 20.78%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Barclays decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. Oppenheimer lifted their price target on Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Thursday, May 30th. Argus raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Tuesday, May 21st. Finally, Citigroup lifted their price target on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $133.75.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.